Enanta Pharmaceuticals (NASDAQ:ENTA) Raised to “Strong-Buy” at Evercore ISI

Evercore ISI upgraded shares of Enanta Pharmaceuticals (NASDAQ:ENTA) to a strong-buy rating in a research report sent to investors on Tuesday morning, Zacks.com reports.

A number of other analysts also recently commented on the stock. JPMorgan Chase & Co. decreased their price objective on shares of Enanta Pharmaceuticals from $11.00 to $10.00 and set an underweight rating on the stock in a report on Tuesday. JMP Securities decreased their price objective on shares of Enanta Pharmaceuticals from $23.00 to $22.00 and set a market outperform rating on the stock in a report on Tuesday, May 7th. HC Wainwright reissued a buy rating and set a $27.00 price objective on shares of Enanta Pharmaceuticals in a report on Tuesday. Finally, StockNews.com raised shares of Enanta Pharmaceuticals from a sell rating to a hold rating in a report on Wednesday, May 8th. One investment analyst has rated the stock with a sell rating, three have given a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Enanta Pharmaceuticals presently has an average rating of Hold and an average target price of $19.00.

Enanta Pharmaceuticals Stock Up 9.1 %

Shares of NASDAQ:ENTA opened at $13.49 on Tuesday. The company has a market cap of $285.70 million, a price-to-earnings ratio of -2.16 and a beta of 0.60. The firm’s 50-day simple moving average is $13.58 and its 200-day simple moving average is $13.75. Enanta Pharmaceuticals has a fifty-two week low of $8.08 and a fifty-two week high of $17.80.

Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its earnings results on Monday, August 5th. The biotechnology company reported ($1.07) earnings per share for the quarter, beating the consensus estimate of ($1.43) by $0.36. The business had revenue of $17.97 million for the quarter, compared to the consensus estimate of $17.44 million. Enanta Pharmaceuticals had a negative net margin of 180.76% and a negative return on equity of 64.85%. The business’s quarterly revenue was down 4.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($1.27) earnings per share. On average, research analysts forecast that Enanta Pharmaceuticals will post -5.95 EPS for the current year.

Insiders Place Their Bets

In other news, insider Tara Lynn Kieffer sold 7,266 shares of the business’s stock in a transaction that occurred on Monday, June 17th. The shares were sold at an average price of $12.33, for a total value of $89,589.78. Following the completion of the transaction, the insider now owns 32,341 shares of the company’s stock, valued at $398,764.53. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. In other news, insider Tara Lynn Kieffer sold 7,266 shares of the business’s stock in a transaction that occurred on Monday, June 17th. The shares were sold at an average price of $12.33, for a total value of $89,589.78. Following the completion of the transaction, the insider now owns 32,341 shares of the company’s stock, valued at $398,764.53. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Scott T. Rottinghaus sold 5,375 shares of the business’s stock in a transaction that occurred on Monday, July 15th. The shares were sold at an average price of $17.08, for a total transaction of $91,805.00. Following the completion of the transaction, the insider now directly owns 21,717 shares of the company’s stock, valued at approximately $370,926.36. The disclosure for this sale can be found here. Over the last quarter, insiders sold 16,940 shares of company stock worth $246,181. Insiders own 13.64% of the company’s stock.

Hedge Funds Weigh In On Enanta Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of ENTA. Vanguard Group Inc. increased its position in Enanta Pharmaceuticals by 7.5% during the first quarter. Vanguard Group Inc. now owns 1,928,078 shares of the biotechnology company’s stock worth $33,664,000 after purchasing an additional 134,292 shares during the last quarter. Federated Hermes Inc. acquired a new position in Enanta Pharmaceuticals during the fourth quarter worth approximately $1,253,000. Farallon Capital Management LLC increased its position in Enanta Pharmaceuticals by 3.5% during the first quarter. Farallon Capital Management LLC now owns 2,095,000 shares of the biotechnology company’s stock worth $36,579,000 after purchasing an additional 70,000 shares during the last quarter. Pennant Investors LP acquired a new position in Enanta Pharmaceuticals during the fourth quarter worth approximately $330,000. Finally, Quest Partners LLC acquired a new position in Enanta Pharmaceuticals during the fourth quarter worth approximately $146,000. Institutional investors and hedge funds own 94.99% of the company’s stock.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.